PURPOSE: We aimed to determine the efficacy and the toxicity of low dose weekly gemcitabine with radiation therapy in medically unfit muscle-invasive bladder cancer patients. METHODS: Twenty-six patients were included into the retrospective analysis. Weekly gemcitabine was administered 75 mg/m(2) with a median dose of 63 Gy radiation therapy. Clinical target volume was defined as the urinary bladder only in conformal treatment planning. RESULTS: Median follow-up was 51 months (range 14-118 months). Complete response rate was 62.5 %. The 5-year local progression-free survival, disease-specific survival and overall survival rates were 40.6, 59.5 and 58.5 %, respectively. Concurrent chemotherapy was continued in 80.7 % of patients without any interruption. Gemcitabine was stopped due to grade 3 thrombocytopenia (n = 1), cardiac angina (n = 1), chronic obstructive pulmonary disease exacerbation (n = 1) or patients' reluctance (n = 2). CONCLUSIONS: Low dose weekly gemcitabine with concurrent radiotherapy is a tolerable regimen and have comparable outcomes with platinum-based combined treatments in muscle-invasive bladder cancer. Prospective randomized trials can help in understanding the safety and efficacy of this treatment specially in medically unfit patients.
PURPOSE: We aimed to determine the efficacy and the toxicity of low dose weekly gemcitabine with radiation therapy in medically unfit muscle-invasive bladder cancerpatients. METHODS: Twenty-six patients were included into the retrospective analysis. Weekly gemcitabine was administered 75 mg/m(2) with a median dose of 63 Gy radiation therapy. Clinical target volume was defined as the urinary bladder only in conformal treatment planning. RESULTS: Median follow-up was 51 months (range 14-118 months). Complete response rate was 62.5 %. The 5-year local progression-free survival, disease-specific survival and overall survival rates were 40.6, 59.5 and 58.5 %, respectively. Concurrent chemotherapy was continued in 80.7 % of patients without any interruption. Gemcitabine was stopped due to grade 3 thrombocytopenia (n = 1), cardiac angina (n = 1), chronic obstructive pulmonary disease exacerbation (n = 1) or patients' reluctance (n = 2). CONCLUSIONS: Low dose weekly gemcitabine with concurrent radiotherapy is a tolerable regimen and have comparable outcomes with platinum-based combined treatments in muscle-invasive bladder cancer. Prospective randomized trials can help in understanding the safety and efficacy of this treatment specially in medically unfit patients.
Authors: Vijay K Sangar; Catherine A McBain; Jeanette Lyons; Vijay A C Ramani; John P Logue; James P Wylie; Noel W Clarke; Richard A Cowan Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: D R Goffinet; M J Schneider; E J Glatstein; H Ludwig; G R Ray; N R Dunnick; M A Bagshaw Journal: Radiology Date: 1975-10 Impact factor: 11.105
Authors: W U Shipley; D S Kaufman; E Zehr; N M Heney; S C Lane; H K Thakral; A F Althausen; A L Zietman Journal: Urology Date: 2002-07 Impact factor: 2.649
Authors: W Tester; A Porter; S Asbell; C Coughlin; J Heaney; J Krall; K Martz; P Venner; E Hammond Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-02 Impact factor: 7.038
Authors: Victor A McPherson; George Rodrigues; Glenn Bauman; Eric Winquist; Joseph Chin; Jonathan Izawa; Kylea Potvin; Scott Ernst; Varagur Venkatesan; Tracy Sexton; Belal Ahmad; Nicholas Power Journal: Can Urol Assoc J Date: 2017 Jan-Feb Impact factor: 1.862